reach semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients achieve substantial weight loss or 💉 Ready to Reach Your

Meal Planning : Plan your meals ahead of time to avoid impulsive food choices

Clinical trial number Not applicable

What Sets Us Apart: Board-certified physicians

For needle-averse patients, the difference between continuing therapy and dropping out can hinge entirely on the delivery method

It has emerged as a life-changing option for overweight or obese people who are committed to shedding a significant amount of weight and do not have other significant underlying health issues

Semaglutides ability to promote significant weight loss can help alleviate the strain that excess weight places on the heart and blood vessels